Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy. Here, we investigated the mechanism by which resistance towards isoniazid develops and how overexpression of efflux pumps favors accumulation of mutations in isoniazid targets, thus establishing a MDR phenotype. The study was based on the in vitro induction of an isoniazid resistant phenotype by prolonged serial exposure of M. tuberculosis strains to the critical concentration of isoniazid employed for determination of drug susceptibility testing in clinical isolates. Results show that susceptible and rifampicin monoresistant strains exposed to this concentration become resistant to isoniazid after three weeks; and that resistance observed for the majority of these strains could be reduced by means of efflux pumps inhibitors. RT-qPCR assessment of efflux pump genes expression showed overexpression of all tested genes. Enhanced real-time efflux of ethidium bromide, a common efflux pump substrate, was also observed, showing a clear relation between overexpression of the genes and increased efflux pump function. Further exposure to isoniazid resulted in the selection and stabilization of spontaneous mutations and deletions in the katG gene along with sustained increased efflux activity. Together, results demonstrate the relevance of efflux pumps as one of the factors of isoniazid resistance in M. tuberculosis. These results support the hypothesis that activity of efflux pumps allows the maintenance of an isoniazid resistant population in a sub-optimally treated patient from which isoniazid genetically resistant mutants emerge. Therefore, the use of inhibitors of efflux should be considered in the development of new therapeutic strategies for preventing the emergence of MDR-TB during treatment.
References
[1]
World Health Organization (2011) Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: World Health Organization.
[2]
Somosk？vi A, Parsons LM, Salfinger M (2001) The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2: 164–168.
[3]
Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, et al. (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647–650.
[4]
Viveiros M, Leandro C, Rodrigues L, Almeida J, Bettencourt R, et al. (2005) Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J Clin Microbiol 43: 4880–4884.
[5]
World Health Organization (2008) Anti-tuberculosis drug resistance in the world. Fourth Global Report. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. 2002–2007. WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization.
[6]
Zhang Y, Heym B, Allen B, Young D, Cole S (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591–593.
[7]
Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227–230.
[8]
Heym B, Alzari PM, Honore N, Cole ST (1995) Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Biol 15: 235–245.
[9]
Guo H, Seet Q, Denkin S, Parsons L, Zhang Y, et al. (2006) Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 55: 1527–1531.
[10]
Vilchèze C, Jacobs WR Jr (2007) The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 61: 35–50.
[11]
Hazbón MH, Brimacombe M, del Valle MB, Cavatore M, Guerrero MI, et al. (2006) Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50: 2640–2649.
[12]
Louw GE, Warren RM, van Pittius NC, McEvoy CR, van Helden PD, et al. (2009) A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 53: 3181–3189.
[13]
Viveiros M, Leandro C, Amaral L (2003) Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents 22: 274–278.
[14]
Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537–544.
[15]
Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, et al. (2010) Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist 16: 21–28.
[16]
Rodrigues L, Aínsa JA, Amaral L, Viveiros M (2011) Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors. Recent Pat Antiinfect Drug Discov 6: 118–127.
[17]
Silva PE, Bigi F, Santangelo MP, Romano MI, Martín C, et al. (2001) Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother 45: 800–804.
[18]
Doran JL, Pang Y, Mdluli KE, Moran AJ, Victor TC, et al. (1997) Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin Diagn Lab Immunol 4: 23–32.
[19]
Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, et al. (2010) jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid and ethambutol. Indian J Med Res 132: 176–188.
[20]
Pasca MR, Guglierame P, De Rossi E, Zara F, Riccardi G (2005) mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Chemother 49: 4775–4777.
[21]
De Rossi E, Arrigo P, Bellinzoni M, Silva PA, Martin C, et al. (2002) The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med 8: 714–724.
[22]
Martinez JL, Baquero F (2000) Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 44: 1771–1777.
[23]
Webber MA, Piddock LJ (2003) The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 51: 9–11.
[24]
Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, et al. (2002) Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46: 2804–2810.
[25]
Pasipanodya JG, Gumbo T (2011) A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 11: 457–463.
[26]
Martins A, Iversen C, Rodrigues L, Spengler G, Ramos J, et al. (2009) An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. Int J Antimicrob Agents 34: 602–604.
[27]
Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, et al. (2008) Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother 61: 1076–1082.
[28]
Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, et al. (2009) The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents 34: 529–533.
[29]
Paix？o L, Rodrigues L, Couto I, Martins M, Fernandes P, et al. (2009) Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J Biol Eng 3: 18.
[30]
Viveiros M, Dupont M, Rodrigues L, Couto I, Davin-Regli A, et al. (2007) Antibiotic stress, genetic response and altered permeability of E. coli. PLoS ONE 2(4): e365.
[31]
de Steenwinkel JE, de Knegt GJ, Kate MT, van Belkum A, Verbrugh HA, et al. (2010) Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 65: 2582–2589.
[32]
Bergval IL, Schuitema ARJ, Klatser PR, Anthony RM (2009) Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 64: 515–523.
[33]
Vijdea R, Stegger M, Sosnovskaja A, Andersen ？B, Thomsen V？, et al. (2008) Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 27: 1079–1086.
[34]
Srivastava S, Musuka S, Sherman C, Meek C, Leff R, et al. (2010) Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethanbutol. J Infect Dis 201: 1225–1231.
[35]
Costa SS, Falc？o C, Viveiros M, Machado D, Martins M, et al. (2011) Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 11: 241.
[36]
Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M (2011) Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol. doi:10.1016/j.meegid.2011.08.009.
[37]
da Silva PEA, Groll AV, Martin A, Palomino JC (2011) Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 63: 1–9.
[38]
Louw GE, Warren RM, van Pittius NC, Leon R, Jimenez A, et al. (2011) Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 184: 269–276.
[39]
DeMarco CE, Cushing LA, Frempong-Manso E, Seo SM, Jaravaza TA, et al. (2007) Efflux-related resistance to norfloxacin, dyes and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 51: 3235–3239.
[40]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25: 402–408.
[41]
Portevin D, de Sousa-D'Auria C, Houssin C, Grimaldi C, Daffé MCM, et al. (2004) A polyketide synthase catalyses the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc Natl Acad Sci USA 101: 314–319.
[42]
Cox JS, Chen B, McNeil M, Jabobs WR Jr (1999) Complex lipid determines tissue replication of Mycobacterium tuberculosis in mice. Nature 52: 2503–2511.
[43]
Bianco MV, Blanco FC, Imperiale B, Forrellad MA, Rocha RV, et al. (2011) Role of P27–P55 operon from Mycobacterium tuberculosis in the resistance to toxic compounds. BMC Infect Dis 11: 195.
[44]
Wilson M, DeRisi J, Kristensen H-H, Imboden P, Rane S, et al. (1999) Exploring drug induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 96: 12833–12838.
[45]
B？ttger EC (2011) The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17: 1128–1134.
[46]
Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, et al. (2011) Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 16: 79–83.
[47]
Inderlied CB, Nash KA (1996) Antimycobacterial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids. pp. 127–175.
[48]
Siddiqi S, Rüsch-Gerdes S (2006) MGIT960 Procedure Manual for BACTEC？ MGIT 960？ TB System (Also applicable for Manual MGIT). Mycobacteria growth indicator tube (MGIT) culture and drug susceptibility demonstration projects. Foundation for innovative new diagnostics Ed.
[49]
Springer B, Lucke K, Calligaris-Maibach R, Ritter C, B？ttger EC (2009) Quantitative drug susceptibility testing of Mycobacterium tuberculosis using MGIT960 ‘and the EpiCenter instrumentation. J Clin Microbiol 47: 1773–1780.
[50]
Perdig？o J, Macedo R, Jo？o I, Fernandes E, Brum L, et al. (2008) Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 14: 133–143.
[51]
Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, et al. (2006) Proposal for standardization of optimized mycobacterial interspersed repetitive unit–variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 44: 4498–4510.
[52]
Viveiros M, Rodrigues L, Martins M, Couto I, Spengler G, et al. (2010) Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol 642: 159–172.
